Trial Profile
A trial to study pharmacokinetic predictors of sorafenib discontinuation and its therapy in hepatocellular carcinoma patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Apr 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics
- 19 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics